Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05108090 · ClinicalTrials.gov registry record · NA

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

A NA study of Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
94
Enrollment target
1
Study location

NCT05108090 is a NA study of Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma that is actively recruiting participants, run by Indiana University. The registered enrollment target is 94 participants, roughly in line with the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05108090, a NA study of Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
94 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.

Interventions

  • PROCEDURE sentinel lymph node biopsy (SLNB)

Study Locations (1)

Indiana

  • Indiana University Melvin & Bren Simon Cancer Center - Indianapolis

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2021-10-25
Est. Completion 2026-09
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT05108090

The ClinicalTrials.gov registry entry for NCT05108090 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which sentinel lymph node biopsy (SLNB) is the first listed.

NCT05108090 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT05108090 about?

NCT05108090 is a clinical study titled "Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck". The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.

What is the current status of trial NCT05108090?

This trial is currently recruiting. It is a NA study. The enrollment target is 94 participants. The study started on 2021-10-25. Estimated completion is 2026-09.

What conditions does trial NCT05108090 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Nonmelanoma Skin Cancer.

What interventions are being tested in trial NCT05108090?

The interventions under investigation include: sentinel lymph node biopsy (SLNB) (PROCEDURE).

Who is sponsoring clinical trial NCT05108090?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05108090 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.